University of Iowa Research Foundation

University of California

Other

Wyeth Holdings Corporation

Michael A Apicella

Bradford W Gibson

Melvin G Sunshine

Na-Gyong Lee

Rasappa Arumugham

Andrew Preston

Nancy J Phillips

Deborah Post

Jennifer L Edwards

Beverly L Davidson

Paul B McCray, Jr

Maria Fortuna-Nevin

Sateesh Krishnamurthy

Anthony Zaleski

Simon Allen

Paul A Jones

Nicole M Samuels

Karoline Scheffler

The present invention relates to methods of reducing a level of a target mRNA in a well-differentiated airway epithelial cell by contacting the cell with a facilitating agent followed by contacting the cell with a therapeutic RNAi agent, wherein the facilitating agent comprises a Platelet-activating factor receptor (PAFR) ligand.

Methods of improving RNAi in well-differentiated airway epithelia

The invention provides lipid A deficient mutantcells, pharmaceutical compositions incorporating such cells, and methods of using such cells.

[object Object]

A method is provided for identifying, isolating, and producing htrB mutants of gram-negative bacterial pathogens. The method comprises mutating the htrB gene of a gram-negative bacterial pathogen so that there is a lack of a functional htrB protein, resulting in a mutant that lacks one or more secondary acyl chains contained in the wild type gram-negative bacterial pathogen, and displays substantially reduced toxicity as compared to the wild type strain. Also, the present invention provides methods for using a vaccine formulation containing the htrB mutant, the endotoxin isolated therefrom, or the endotoxin isolated therefrom which is then conjugated to a carrier protein, to immunize an individual against infections caused by gram-negative bacterial pathogens by administering a prophylactically effective amount of the vaccine formulation.

Non-toxic mutants of pathogenic gram-negative bacteria

This invention relates to purified sialic acid permease systems, and inhibitory agents of sialic acid permease systems.

Sialic acid permease system

The present invention is directed to sialytransferases, such as SiaA sialytransferases isolated from. Further provided herein are methods for producing sialylated lipooligosaccharides, vaccines, and host cells and systems for the production of sialylated lipooligosaccharides.

The present invention is directed to compounds and methods for immunizing a patient against a biofilm-producing bacterial infection and a vaccine related thereto.

Vaccine and method for preventing biofilm formation

The present invention is directed to novel polypeptides, polynucleotides and vaccines for use againstcolonization or infection and/orcolonization or infection. The vaccines contain an immunogenic amount of a neisserial protein.

Vaccine and compositions for the prevention and treatment of neisserial infections

The present invention is directed to novel polypeptides, polynucleotides and vaccines for use againstcolonization or infection. The vaccines contain an immunogenic amount of a neisserial protein.

A method is provided for identifying, isolating, and producing htrB mutants of gram-negative bacterial pathogens. The method comprises mutating the htrB gene of a gram-negative bacterial pathogen so that there is a lack of a functional HtrB protein, resulting in a mutant that lacks one or more secondary acyl chains and displays substantially reduced toxicity as compared to the wild type strain. Also, the present invention provides methods for using a vaccine formulation containing the htrB mutant, or the endotoxin isolated therefrom, to immunize an individual against infections caused by gram-negative bacterial pathogens by administering a prophylactically effective amount of the vaccine formulation.

The present invention discloses a mutanthaving extensive membrane blebbing, both an indicium and a cause of virulence in the gonococcus and meningococcus. Methods are disclosed for making and characterizing the mutant, bmrRS. Methods are disclosed for isolating bmrRS membranes for use as a vaccine. Methods are also disclosed for the use of the mutant for determining the virulence of clinical samples ofand. Methods are also disclosed for the screening of antibiotics targeted to virulent

Two-component system that controls bacterial membrane synthesis

Compositions and methods for making complex carbohydrates in a bacterial production cell are disclosed. The complex carbohydrates that can be made include oligosaccharides and polysaccharides of bacterial or mammalian origin.

Production of complex carbohydrates

Antigenic conjugates are provided which comprise a carrier protein covalently bonded to the conserved portion of a lipopolysaccharide of a gram negative bacteria, wherein the conserved portion of the lipopolysaccharide comprises the inner core and lipid A portions of the lipopolysaccharide, the conjugate eliciting a cross reactive immune response against heterologous strains of the gram negative bacteria.

Growing community of inventors

Solon, IA, United States of America

Michael A Apicella